Published data linking the overexpression of HER2 and/or the amplification of the c-erbB2 gene with chemoresistance and overall poor survival in USC exist, as previously mentioned; the potential prognostic role of HER2 biomarker in uterine tumors other than serous carcinoma is still under research. The gene discussed is ERBB2; the disease is serous adenocarcinoma.